Transarterial Chemoembolization Of Hepatocellular Carcinoma: Can Early Diffusion Weighted Imaging Predict Response?

Gulzar Asma, Shera Tahleel, Shah Omair, Choh Naseer, Gojwari Tariq, Bhat Mudaisr, Maqsood Shadab
{"title":"Transarterial Chemoembolization Of Hepatocellular Carcinoma: Can Early Diffusion Weighted Imaging Predict Response?","authors":"Gulzar Asma, Shera Tahleel, Shah Omair, Choh Naseer, Gojwari Tariq, Bhat Mudaisr, Maqsood Shadab","doi":"10.18502/bccr.v13i1.8834","DOIUrl":null,"url":null,"abstract":"PURPOSE: We evaluated the role of early diffusion weighted imaging (DWI) in predicting response to TACE in patients with HCC and compare the results with contrast enhanced magnetic resonance imaging. Methods: 24 patients with documented HCC were taken up for TACE after a pre-procedural contrast CT and MRI. Post procedural DWI was taken on day 5-7 and the mean ADC values were documented and compared to pre procedural values. The change in ADC values was grouped into 4 categories: group 1- <25%, group 2 26-50%, group 3- 51-75% and group 4- >75%. The increase in ADC values signifying response was correlated with 5 week CEMRI scan (which has been the traditional gold standard for response evaluation) and a threshold ADC increase signifying response in majority of the cases was calculated. Results: The mean ADC of the lesions changed from 1.21× 10-3 (pre TACE) to 2.02× 10-3 mm2/sec (post TACE) [p<0.001]. Taking CE MRI as gold standard, DWI imaging had a sensitivity of 80%, specificity of 94.7% with a positive predictive value of 80%, negative predictive value of 94.7% and overall accuracy of 91.7%. Complete response was seen in19 (79%) and incomplete in 5 (21%) patients in our study. The change in ADC was significantly higher in responders (884.15 ± 161.60) as compared to non responders (564.80 ± 221.05) [p =0.001]. Conclusion: Early DWI after TACE can predict response of a HCC lesion to chemoembolization. The change in ADC values can earmark responders from non-responders. Early DWI results are concordant with CEMRI results in most of the cases. DWI can act as a substitute to CEMRI when contrast administration is not advised.","PeriodicalId":8706,"journal":{"name":"Basic & Clinical Cancer Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Cancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/bccr.v13i1.8834","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

PURPOSE: We evaluated the role of early diffusion weighted imaging (DWI) in predicting response to TACE in patients with HCC and compare the results with contrast enhanced magnetic resonance imaging. Methods: 24 patients with documented HCC were taken up for TACE after a pre-procedural contrast CT and MRI. Post procedural DWI was taken on day 5-7 and the mean ADC values were documented and compared to pre procedural values. The change in ADC values was grouped into 4 categories: group 1- <25%, group 2 26-50%, group 3- 51-75% and group 4- >75%. The increase in ADC values signifying response was correlated with 5 week CEMRI scan (which has been the traditional gold standard for response evaluation) and a threshold ADC increase signifying response in majority of the cases was calculated. Results: The mean ADC of the lesions changed from 1.21× 10-3 (pre TACE) to 2.02× 10-3 mm2/sec (post TACE) [p<0.001]. Taking CE MRI as gold standard, DWI imaging had a sensitivity of 80%, specificity of 94.7% with a positive predictive value of 80%, negative predictive value of 94.7% and overall accuracy of 91.7%. Complete response was seen in19 (79%) and incomplete in 5 (21%) patients in our study. The change in ADC was significantly higher in responders (884.15 ± 161.60) as compared to non responders (564.80 ± 221.05) [p =0.001]. Conclusion: Early DWI after TACE can predict response of a HCC lesion to chemoembolization. The change in ADC values can earmark responders from non-responders. Early DWI results are concordant with CEMRI results in most of the cases. DWI can act as a substitute to CEMRI when contrast administration is not advised.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肝细胞癌经动脉化疗栓塞:早期弥散加权成像能预测疗效吗?
目的:我们评估早期弥散加权成像(DWI)在预测HCC患者对TACE的反应中的作用,并将结果与增强磁共振成像进行比较。方法:24例确诊HCC患者行术前对比CT和MRI检查后行TACE。术后第5-7天取DWI,记录平均ADC值,并与术前值进行比较。ADC值变化分为4组:1组- 75%组。表明缓解的ADC值的增加与5周的CEMRI扫描(这是评估缓解的传统金标准)相关,并且计算了大多数情况下表明缓解的阈值ADC增加。结果:病变的平均ADC由TACE前的1.21× 10-3 mm2/sec变为TACE后的2.02× 10-3 mm2/sec [p<0.001]。以CE MRI为金标准,DWI成像的敏感性为80%,特异性为94.7%,阳性预测值为80%,阴性预测值为94.7%,总体准确率为91.7%。在我们的研究中,19例(79%)患者出现完全缓解,5例(21%)患者出现不完全缓解。有应答者ADC的变化(884.15±161.60)明显高于无应答者(564.80±221.05)[p =0.001]。结论:TACE术后早期DWI可以预测肝癌病变对化疗栓塞的反应。ADC值的变化可以区分有反应者和无反应者。多数病例早期DWI结果与CEMRI结果一致。当不建议使用造影剂时,DWI可以替代CEMRI。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
16
审稿时长
12 weeks
期刊最新文献
The Effect of Ursodeoxycholic acid and N-acetyl cysteine on Lymphoblast Viability Cross-Reacting Material 197, a Specific Inhibitor of HB-EGF, and Its Anticancer Effects Chronic Myeloid Leukemia in a Young Man with Unusual Presentation of Weight Loss, Bone Pain, and Abdominal Pain Effects of Gold Nanoparticles on Proton Therapy for Breast Cancer Cancer has an Independent Association with Death in Hospitalized Patients with COVID-19: A Single-center Study in Iran
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1